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This study was undertaken to assess endogenous Na+,K+-ATPase inhibitors in both plasma and urine in 
the same subjects. Samples were chromatographed on reverse-phase HPLC using an a&on&rile gradient 
and the eluent screened using Na+,K+-ATPase inhibition and cross-reaction with anti-digoxin antibodies. 
The donors were divided into inhibiting and non-inhibiting subjects using a previously described method, 
plasma action on ouabain binding and on Na+,K+-ATPase activity. Three Na+,K+-ATPase inhibitors (lP, 
2P and 3P) were detectable in plasma; the antibodies cross-reaction of the peaks 2P and 3P were larger 
than that of peak 1P. The peaks 2P and 3P were significantly higher in inhibiting subjects as compared 
to non-inhibiting subjects. The 24-h urine is resolved into two peaks inhibiting Na+,K+-ATPase activity 
(IU and 2U). Peak 2U cross-reacted with antidigoxin antibodies to a greater extent than peak 1U and 
is significantly larger in inhibiting subjects in terms of Na+,K+-ATPase inhibition. These data support the 
heterogeneity of human Na+,K+-ATPase inhibitor in both plasma and urine. 
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1. INTRODUCTION 
An increased activity or concentration of an en- 
dogenous Na+,K+-ATPase inhibitor or inhibitors 
has been associated with hypertension in humans 
[l-3] and animals [4]. While the existence of this 
endogenous factor(s) is generally accepted, the 
number and structure of the inhibitor(s) is yet to be 
determined. For example, two inhibitors were 
found in the plasma of salt-loaded dogs [5,6], 3 in 
the plasma of healthy humans [7], 4 in the plasma 
of patients with fulminant hepatic failure [8] and 
only 1 in the plasma of uremic patients [9]. In con- 
trast, only a single active substance has been iden- 
tified in the urine of salt-loaded humans [lO-141 or 
salt-loaded dogs [ 151. The confusion is compound- 
ed by the fact that plasma and urine samples of the 
same subjects have not been compared. 
and determination of the Na+,K+-ATPase in- 
hibiting substances have also varied. The reported 
methods include chromatography on Sephadex 
G-25 [f&9,13], ion-exchange chromatography [7], 
and combinations of ion-exchange and reverse- 
phase chromatography [5,6,15]. The same method 
has not been applied to both plasma and urine. 
The analytical approaches to the separation 
We report the development of a reverse-phase 
high performance liquid chromatographic (HPLC) 
method coupled with biological tests for the isola- 
tion of endogenous Na+,K+-ATPase inhibitors 
and the application of this method to plasma and 
urine samples from the same subjects. The study 
included subjects with inhibiting and non-inhibiting 
plasma [2,16,17]. The main findings are: (i) in- 
hibiting and non-inhibiting plasma contain 3 frac- 
tions which inhibit Na+,K+-ATPase, two of which 
cross-react with antidigoxin antibodies; (ii) the en- 
zyme active fractions in the inhibiting plasma are 
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significantly larger than those of the non-inhibiting 
plasma; (iii) the corresponding urine samples con- 
tain two inhibiting fractions, one of which is anti- 
body active;, and (iv) the peak inhibition of the 
enzyme activity of antibody active fraction is sig- 
nificantly greater for subjects with inhibiting 
plasma. 
termined at a dilution of 1 to 20. The positive and 
negative urines were obtained from people having 
inhibiting and non-inhibiting plasma, respectively. 
2.4. High-performance liquid chromatography 
2. MATERIALS AND METHODS 
2.1. Patients and subjects 
Essential hypertensive patients and normoten- 
sive subjects were used in the study. The essential 
hypertensive patients came from the Hypertension 
Unit of Necker Hospital and had been off medica- 
tion for at least one week. They were on regular 
Na+ diet (100-120 mmol/24 h). Their blood pres- 
sures exceeded 160-90mmHg when measured ac- 
cording to the recommendations of the WHO [ 181. 
The normotensive subjects, both with and without 
genetic history of hypertension, were also free of 
any form of medication for at least a week. 
The plasma and urine samples were chromato- 
graphed using a gradient-capable HPLC system 
(LKB-Product AB, Bromma, Sweden) equipped 
with a UV detector set at 226 nm. The chromato- 
graphy was carried out on a 5~ Lichrosorb RP18 
column (Merck, Darmstadt) using elution gra- 
dients of O-50% acetonitrile in water at a flow rate 
of 1 ml/min. The mobile phase contained 0.1% 
trifluoroacetic acid and all the solvents were J.T. 
Baker HPLC grade (Sochibo, Boulogne-sur-Seine). 
Three 200~~1 injections of each sample were chro- 
matographed under these conditions and the eluent 
was collected in one-minute fractions. The frac- 
tions were freeze-dried, reconstituted to l/10 of 
the initial volume with 10e3 M acetic acid and 
tested. 
2.5. Bio-assays 
2.2. Sample preparation 
Blood samples were collected in chilled, hepari- 
nized tubes between 9 and 11 a.m. Since it had 
previously been reported that the endogenous 
Na+,K+-ATPase inhibitor is heat stable [2,7], the 
plasma was immediately separated from the cells 
(3000 x g, 5 min, 4°C) and boiled for 15 min. The 
time between blood sampling and the beginning of 
the boiling never exceeded 15 min. After cooling, 
the resulting clot was disrupted and centrifuged for 
20 min at 4OC at 10 000 x g. The supernatants were 
collected and stored at -20°C until analysis. 
The HPLC residues were assessed for their 
capacity to inhibit Na+,K+-ATPase activity and to 
cross-react with anti-digoxin antibodies. The plas- 
mas were then tested at a final concentration of 1 
and 3 times the initial concentration 
activity and antibodies, respectively. 
were assessed at a final concentration 
30 times the initial concentration for 
activity and antibodies, respectively. 
2.6. Na+,K+-ATPase 
A total 24-h urine, covering the day previous to 
the blood sampling, was collected from partici- 
pants. A lOm1 aliquot was freeze-dried and then 
stored at -2O’C. The samples were reconstituted 
using 1 ml of bidistilled water just before analysis. 
2.3. Determination of inhibiting and non-inhibiting 
plasma 
Inhibiting and non-inhibiting plasma were deter- 
mined according to their capacity to inhibit both 
dog kidney Na+,K+-ATPase activity [16,17] and 
ouabain binding to human erythrocytes [2,16]. In 
brief, the plasma inhibition of Na+,K+-ATPase 
was assessed using a plasma concentration of 2; 
and the plasma effect on ouabain binding was de- 
Dog kidney Na+,K+-ATPase (1.6pg protein, 
EC3.6.1.3,Sigma)~asincubatedat37~Cfor45min 
in the following medium: 80mM Tris-HCl, 
1 mM EGTA, 2 mM ATP (vanadate free, Sigma), 
O.O2pCi/ml [Y-~~P]ATP (3000 Ci/mmol, Amer- 
sham), 3 mM MgClz, 100 mM NaCl, 5 mM KCl, 
pH 7.4. The fractions from HPLC were assessed at 
a dilution of 1 to 10 in the incubating medium 
volume of 120~1. Blanks were obtained by parallel 
incubation performed in the absence of K+ and the 
presence of 0.1 mM ouabain. The reaction was 
stopped by sudden cooling at 4°C and by addition 
of cold perchloric acid (10% final concentrations). 
Then, 0.5 ml of cold charcoal suspension (20%, 
w/v) was added, and after 5 min the mixture was 
spun down for 3 min at 15 000 x g. The resulting 
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su~~atant was analyzed for its 32P content in a 
liquid scintillation counter. The difference between 
the incubation in the absence and presence of 
ouabain was considered as the Na+,K+-ATPase 
activity which represented 9%98% of the total en- 
zyme activity. The effects of various HPLC frac- 
tions were expressed as percentages of in~bition of 
the ouabain-sensitive ATPase in the HPLC pat- 
terns. The activities of various peaks inhibiting 
Na*,K+-ATPase were expressed by the sums of the 
percentage of inhibition (higher than 10%) of 
tubes present in the peak, divided by the number of 
these tubes, and also by the maximum inhibitory 
value obtained in each peak. 
2.1. Antibodies 
The procedure for measurement of digoxin im- 
munoreactivity was essentially that described in 
flQ] using a kit from NEN. The effect of various 
HPLC fractions were expressed as digoxin equiva- 
lent concentration i  nm/ml of HPLC fractions 
for the HPLC patterns. Since a non-parallelism 
was obtained between the digoxin standard curves 
and the fractions dilution curves, it is not possible 
to calculate a digoxin equivalent concentration i
the peaks. 
3. RESULTS 
The boiled plasma supernatants from inhibiting 
(positive, it = 5) and non-~biting (negative, 
n = 4) plasma were analyzed by reverse-phase 
HPLC using an acetonitrile-water gradient. The 
resnlting c~omatogr~s contained 3 peaks (lP, 
2P, 3P) which inhibited Na+,K+-ATPase and cross- 
reacted with antibodies raised against digoxin 
(fig.1). The peaks eluted at acetonitrile concentra- 
tions of 23, 29 and 34%, respectively. A fourth 
peak which cross-reacted with antibodies but did 
not inhibit Na+,K+-ATPase was also detected 
(acetonitrile = 369’0). 
Peak 1P was present in both positive and nega- 
tive plasma nd there was no significant difference 
between the peaks from the two plasmas when the 
maximum or average inhibition of Na+,K+-ATPase 
was measured (table 1). Peaks 2P and 3P were also 
present in all plasmas, however, the maximum and 
average Na’,K+-ATPase inhibition measured for 
these peaks in the positive plasmas were signifi- 
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Fig. 1. HPLC of ZOO-~1 injection of supernatant of boiled 
plasma on 5~ Lichrosorb RF18 (250 x 4 mm). Chro- 
m~o~aphy was developed using an acetonitrile gradient 
(lower panel, II). The optical density was recorded 
at 226nm (lower panel, -). l-mm fractions were 
collected, freeze&ii and assessed for their capacity to 
inhibit dog kidney Na+,K+-ATPase activity (upper 
panel, a---a) and to cross-react with anti-digoxin 
antibodies (upper panel, A---A). 
cantly higher than the values found in the negative 
plasmas (table 1). 
Urine samples from subjects with inhibiting 
(positive urine, n = 3) and non-inhibiting (negative 
urine, n = 3) plasmas were also analyzed by reverse- 
phase HPLC using an acetonitrile-water gradient. 
The resulting c~omatogr~s contained two peaks 
(lU, 2U) which inhibited Na+,K+-ATPase and 
cross-reacted with antibodies raised against digoxin 
(fig.2). The peaks eluted at acetonitrile concentra- 
tions of 18 and 28%. A third peak which cross- 
reacted with antibodies but did not inhibit Na+,K’- 
ATPase was also detected (acetonitrile = 38010). 
Peak 1U was present in the urine from all the 
subjects and there was no significant difference in 
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Peak Positives” Negatives* 
Subjects Plasma Urine Subjects Plasma Urine 
b f b f b c b E 
1 1 
2 
3 
4 
5 
71 
88 
85 
15 
90 
69.8 
15.8 
72 
88 
88 
84 
49 
76.2d 
8.3 
3 1 75 
2 61 
3 88 
4 62 
5 63 
57 66 
73 100 
59 -< 
15 - 
52 17 
51.2 61.0 
15.8 29.5 
56 57 
57 48 
50 - 
65 - 
31 36 
51.6d 47.0’ 
6.3 7.4 
54 
39 
53 
48 
45 
69.gf 47.8” 
5.8 3.1 
40 
86 
16 
90 68 40 
19 18 13 
12 12 21 
40 32 - 
36 
13 
16 
35.1 
5.9 
0 
12 
17 
9.4 
6.0 
47.6 mean 40.2 
25.1 *SE 20.3 
32.5 24.7 
14.5 9.8 
12 0 
14 14 
15 21 
13 - 
*SE 
2 1 
2 
3 
42 
37 
26 
12 
15 
18 
13 
21.4 
9.0 
14.5 
1.5 
13.5 11.7 
0.7 7.6 
21 
12 
17 
36 
*SE &SE 
24 
13 
17 
83 
29.2 21.5 
13.2 6.0 *SE 
‘Positive subjects (giving inhibiting plasma) and negative subjects (giving non-inhibiting plasma) were determined 
according to the capacity of boiled plasma supematant o inhibit dog kidney Na+,K+-ATPase [16,17] and ouabaln 
binding to human erythrocytes [2,16] 
bMaximum value of Na+,K”-ATPase inhibition for each peak 
’ Average of the inhibition of the Na” ,K+-ATPase activity of each peak. The data were analyzed using the Student t-test, 
positives vs negatives: d P < 0.001; ‘P < 0.01; f P < 0.02 
- Indicates that the urines of this subject were not analyzed. 
rn~rn~ or average Na*,K+-ATPase ambition 
between this peak in the positive urine and the cor- 
responding peak in the negative urine (table 1). 
Peak 2U was present in all the positive urines but 
was only detected in 2 out of the 3 negative urines. 
The maximum value of the Na+,K+-ATPase in- 
hibition for peak 2U in the positive urine was sig- 
nificantly greater than the corresponding value for 
the negative urine. However, there was no signifi- 
cance in the average inhibition of these peaks. 
4. DISCUSSION 
Our results are in good agreement with the pre- 
viously described heterogenicity of human plas- 
matic NaS,K+-ATPase inhibitors (S-81 and the 
increasing level of circulating Na+,K+-ATPase in- 
hibitors in hypertensives [l-3]. The identification 
of two urinary Na+,K+-ATPase inhihitors, how- 
ever, is not consistent with previous reports of a 
single inhibitor [ 1 O- 141. This discrepancy could be 
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Fig.2. HPLC of 200-~1 injection of 10 times concen- 
trated urine on 5/r Lichrosorb RP18 (250 x 4mm). 
Chromatography was developed as in fig.1. 
due to methodological differences arising from the 
employment here of gradient-elution reverse-phase 
HPLC. 
Our data suggest a connection between the 
amount of Na+,K+-ATPase inhibitors found in the 
plasma and urine of the same subject. This is con- 
sistent with the observed correlation between the 
Na+,K+-ATPase level in plasma measured by 
ouabain binding and in urine measured by affinity 
chromatography in the same subject [21,22]. 
The significant difference in the maximum and 
average Na+,K+-ATPase inhibition for peaks 2P 
and 3P in inhibiting plasma vs non-inhibiting 
plasma and the corresponding difference in maxi- 
mum inhibition for peak 2U in urine leads to the 
conclusion that the first peaks are not related to 
hypertension while peaks 2P, 3P and 2U appear to 
be specific for this disease. 
Unfortunately, this tentative conclusion is only 
supported by the results of the Na+,K+-ATPase in- 
hibition. It was not possible to draw the same con- 
clusion using the cross-reaction with antidigoxin 
antibodies since the digoxin standard curves were 
not parallel to peak dilution curves, and it was not 
possible to estimate the equivalent digoxin concen- 
tration of the plasmatic and urinary peaks. How- 
ever, in both fluids, the cross-reaction of the first 
peak (lP, 1U) with antibodies raised against digoxin 
is lower than that of the other peaks. Therefore, 
these data supported the possible immunological 
similarity between the endogenous Na+,K+-ATPase 
inhibitors and digoxin. 
The retention times and eluting acetonitrile per- 
centage of peaks 1P and 2P are close to those of 
peaks 1U and 2U, respectively. Nevertheless, this 
comparison is not sufficient to support the identity 
of peaks 1P and lU, and 2P and 2U. If the peaks 
1P and 2P are similar to the peaks 1U and 2U, 
respectively, it is possible that both peak 2P and 
peak 2U may represent a metabolite of the peak 
3P. The further purification and identification of 
these peaks, as well as peak 3P, is currently in 
progress. 
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